Oncology News and Research

RSS

Oncology, meaning bulk, mass, or tumor, and the suffix ''-logy'', meaning "study of") is a branch of medicine that deals with tumors (cancer). A medical professional who practices oncology is an ''oncologist''.

Study estimates demand for radiation therapy will increase by 22% over next decade

Between 2010 and 2020, the demand for radiation therapy will exceed the number of radiation oncologists practicing in the U.S. tenfold, which could profoundly affect the ability to provide patients with sufficient access to treatment, according to new research from The University of Texas MD Anderson Cancer Center.

19 Oct 2010

Amgen to review study results of ESA in chronic renal failure patients with FDA and CRDAC

Amgen will review the results from TREAT (the Trial to Reduce Cardiovascular Events with Aranesp® Therapy) and will discuss how these results inform the appropriate use of erythropoiesis-stimulating agents (ESAs) for chronic renal failure (CRF) patients at today's meeting of the Food and Drug Administration's (FDA) Cardiovascular and Renal Drugs Advisory Committee (CRDAC).

19 Oct 2010

Novartis announces six-year data of Reclast injection for postmenopausal women with osteoporosis

Novartis announced today that new six-year data reinforce the long-term efficacy and safety profile of once-yearly Reclast (zoledronic acid) injection in postmenopausal women with osteoporosis.The study of more than 1,200 women was presented this weekend at the annual meeting of the American Society for Bone and Mineral Research (ASBMR) in Toronto, ON, Canada.

19 Oct 2010

EMA Pediatric Committee adopts positive opinion for CTI's Pixuvri for lymphoid malignancies, solid tumors

Cell Therapeutics, Inc. ("CTI") announced today that the Pediatric Committee (the "PDCO") of the European Medicines Agency ("EMA") has adopted an opinion agreeing to CTI's Pixuvri® (pixantrone dimaleate) Pediatric Investigation Plan ("PIP") for the treatment of lymphoid malignancies and solid tumors in children between ages of 6 months and 18 years.

19 Oct 2010

Study: Half of Canadians with osteoporosis have insufficient levels of vitamin D

New data presented today at the American Society for Bone and Mineral Research 2010 Annual Meeting held in Toronto, Ontario, demonstrated that approximately half of Canadians with osteoporosis have insufficient levels of vitamin D (less than 80 nmol/L), despite the fact that more than 40 per cent are prescribed at least 2800 IU of vitamin D per week.

19 Oct 2010

NCCN updates Clinical Practice Guidelines for Breast Cancer

The National Comprehensive Cancer Network® (NCCN®) recently updated the NCCN Clinical Practice Guidelines for Oncology (NCCN Guidelines™) for Breast Cancer to affirm the recommendation regarding the use of bevacizumab (Avastin®, Genentech/Roche) in the treatment of metastatic breast cancer.

19 Oct 2010

Researchers to test nanoparticle-based theranostics for pancreatic cancer treatment

Researchers from Rice University's Laboratory for Nanophotonics (LANP), the radiology department at Baylor College of Medicine (BCM) and the University of Texas MD Anderson Cancer Center are preparing to test a combined approach for diagnosing and treating pancreatic cancer with a specially engineered nanoparticle.

19 Oct 2010

Karmanos Cancer Institute awarded $3M NIH grant to study triple-negative breast cancer

Scientists at the Barbara Ann Karmanos Cancer Institute in Detroit have received a nearly $3 million, five-year research project (RO1) grant from the National Institutes of Health to study a potentially ground-breaking immunotherapy treatment for women with one of the deadliest forms of breast cancer – triple-negative breast cancer. The research is exclusive to the Karmanos Cancer Institute.

19 Oct 2010

Novel bioelectric signals can cause stem cells to trigger melanoma-like growth in pigment cells

Biologists at Tufts University School of Arts and Sciences have discovered that a change in membrane voltage in newly identified "instructor cells" can cause stem cells' descendants to trigger melanoma-like growth in pigment cells. The Tufts team also found that this metastatic transformation is due to changes in serotonin transport. The discovery could aid in the prevention and treatment of diseases like cancer and vitiligo as well as birth defects.

19 Oct 2010

New motion management software enables clear visualization of moving tumors in lung cancer

A 67-year-old female patient with lung cancer presented physicians with a difficult challenge: her tumor was small and it rode up and down with her breathing. During her treatment set up, all doctors saw on their therapy system's imaging equipment was a blur of motion. Fortunately, Leeds Teaching Hospitals NHS Trust was able to utilize its Symmetry motion management software; new imaging technology from Elekta that enables clear visualization of moving targets.

From Elekta 19 Oct 2010

OncoGenex announces public offering of common stock

OncoGenex Pharmaceuticals, Inc. today announced that it is commencing a public offering of its common stock and warrants to purchase shares of its common stock.

19 Oct 2010

Groundbreaking melanoma clinical trial initiated by Patrys

Patrys Limited (ASX: PAB), which is focused on developing revolutionary treatments for cancer, announced today the treatment of the first patient in a human clinical trial to evaluate PAT-SM6 as a therapy for melanoma.

18 Oct 2010

BioSante enrolls 2,500th woman in LibiGel Phase III cardiovascular and breast cancer safety study

BioSante Pharmaceuticals, Inc. today announced enrollment of the 2,500th woman in the LibiGel (testosterone gel) Phase III cardiovascular and breast cancer safety study. This important enrollment milestone triggers the first unblinded statistical analysis of cardiovascular events by the independent Data Monitoring Committee (DMC), which coincides with their fourth unblinded review of all adverse events.

18 Oct 2010

EC grants orphan drug designation to S*BIO's SB1518 for treatment of myelofibrosis

S*BIO Pte Ltd today announced that the European Commission (EC) has granted orphan drug designation to SB1518, its potent and orally active JAK2 inhibitor for the treatment of primary myelofibrosis (PMF), post-polycythemia vera myelofibrosis (PPV-MF) and post-essential thrombocythemia myelofibrosis (PET-MF). SB1518 has also received orphan drug designation from the U.S. Food and Drug Administration (FDA) for the treatment of the same disorder.

18 Oct 2010

Nektar presents data of NKTR-181 mu-opioid analgesic candidate at Pain 2010 Symposium

Nektar Therapeutics presented promising data today from preclinical studies of NKTR-181, a next-generation mu-opioid analgesic candidate with a novel molecular design. NKTR-181 is being developed to effectively treat pain while addressing the abuse liability and serious side effects associated with traditional opioid therapies.

18 Oct 2010

ASTRO honors founder of The Oral Cancer Foundation

The American Society for Radiation Oncology (ASTRO) has named Brian Hill of Newport Beach, Calif., as its 2010 Survivor Circle Award winner. Hill will be recognized with a trophy and a $1,000 prize during the Awards Ceremony on Tuesday, November 2, 2010, during ASTRO's 52nd Annual Meeting in San Diego. He has chosen to donate the funds from the award to benefit The Oral Cancer Foundation, the nonprofit he started a decade ago.

18 Oct 2010

Celgene acquires Abraxis BioScience

Celgene Corporation today announced it has completed its acquisition of Abraxis BioScience, Inc. For each share of Abraxis common stock, Abraxis shareholders will receive (i) $58.00 in cash (ii) 0.2617 shares of Celgene common stock, and (iii) one tradeable Contingent Value Right (CVR), which entitles its holder to receive a pro rata share of potential payments for future regulatory milestones and commercial royalties.

18 Oct 2010

Neogenix to present NPC-1C antibody data at ASCO Annual Meeting

Neogenix Oncology, Inc. announced today that it will present data from its new serum biomarker ELISA utilizing its NPC-1C antibody for patients with colorectal and pancreatic cancers. Results from the study will be presented at the American Society of Clinical Oncology (ASCO)-NCI-EORTC Annual Meeting on Molecular Makers in Cancer, to be held in Hollywood, Florida from October 18-20, 2010.

18 Oct 2010

Nektar presents NKTR-181 preclinical data at ASA 2010 Annual Meeting

Nektar Therapeutics today presented new preclinical data demonstrating that NKTR-181, a mu-opioid analgesic with a novel molecular structure, dramatically reduces abuse liability while providing analgesia comparable to oxycodone and morphine.

18 Oct 2010

PTC announces ataluren Phase 2b efficacy data at International Congress

PTC Therapeutics, Inc. today announced that final analyses of Phase 2b efficacy data suggest the investigational new drug ataluren slowed the loss of walking ability in patients with nonsense mutation dystrophinopathy, a disease continuum comprising Duchenne and Becker muscular dystrophy (nmDBMD). These data were presented at the International Congress of the World Muscle Society in Kumamoto, Japan and will be the basis of interactions with the U.S. Food and Drug Administration (FDA) and national regulatory authorities in Europe in the fourth quarter of 2010.

18 Oct 2010

Oncology News and Research

Further Reading

Study estimates demand for radiation therapy will increase by 22% over next decade

Amgen to review study results of ESA in chronic renal failure patients with FDA and CRDAC

Novartis announces six-year data of Reclast injection for postmenopausal women with osteoporosis

EMA Pediatric Committee adopts positive opinion for CTI's Pixuvri for lymphoid malignancies, solid tumors

Study: Half of Canadians with osteoporosis have insufficient levels of vitamin D

NCCN updates Clinical Practice Guidelines for Breast Cancer

Researchers to test nanoparticle-based theranostics for pancreatic cancer treatment

Karmanos Cancer Institute awarded $3M NIH grant to study triple-negative breast cancer

Novel bioelectric signals can cause stem cells to trigger melanoma-like growth in pigment cells

New motion management software enables clear visualization of moving tumors in lung cancer

OncoGenex announces public offering of common stock

Groundbreaking melanoma clinical trial initiated by Patrys

BioSante enrolls 2,500th woman in LibiGel Phase III cardiovascular and breast cancer safety study

EC grants orphan drug designation to S*BIO's SB1518 for treatment of myelofibrosis

Nektar presents data of NKTR-181 mu-opioid analgesic candidate at Pain 2010 Symposium

ASTRO honors founder of The Oral Cancer Foundation

Celgene acquires Abraxis BioScience

Neogenix to present NPC-1C antibody data at ASCO Annual Meeting

Nektar presents NKTR-181 preclinical data at ASA 2010 Annual Meeting

PTC announces ataluren Phase 2b efficacy data at International Congress

eBook: Liquid biopsy in cancer research eBook

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News